NCT03309878View on ClinicalTrials.gov

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

January 6, 2021

Study Completion Date

April 11, 2023

Conditions
Recurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory High Grade B-Cell LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

Mogamulizumab

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

95817

University of California Davis Comprehensive Cancer Center, Sacramento

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03309878 - Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma | Biotech Hunter | Biotech Hunter